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SUMMARY  
Aims:  Whether atrial fibrillation is related to risk of venous thromboembolism (VTE) is not 
extensively studied. Therefore, we investigated the association between atrial fibrillation and 
future risk of VTE in a population-based cohort.   
Methods: In total, 29 975 subjects were recruited from three surveys of the Tromsø study and 
followed from enrolment (1994-95, 2001-02 and 2007-08) through 2010. Incident events of 
atrial fibrillation and VTE during follow-up were recorded. Information on potential 
confounders was obtained at baseline. Cox-regression models with atrial fibrillation as time-
dependent variable were used to calculate hazard ratios (HR) for VTE with 95% confidence 
intervals (CI).  
Results: During 16 years of median follow-up, 1604 subjects were diagnosed with atrial 
fibrillation and 614 with incident VTE. The risk of VTE was substantially increased during 
the first 6 months after diagnosis of atrial fibrillation (HR 8.44, 95% CI: 5.61-12.69), and 
remained increased throughout the study period (HR: 1.43, 95% CI 1.43-1.99) compared to 
those without atrial fibrillation. Atrial fibrillation displayed higher risk estimates for 
pulmonary embolism (HR: 11.84, 6.80-20.63) than for deep vein thrombosis (HR: 6.20, 3.37-
11.39), during the first 6 months, and was still associated with pulmonary embolism (HR: 
1.96, 95% CI: 1.24-3.10) but not with deep vein thrombosis (HR: 1.08, 95% CI: 0.66-1.75) 
more than 6 months after diagnosis.  
Conclusion: Atrial fibrillation was associated with increased risk of VTE, and pulmonary 
embolism in particular. Our findings support the concept that isolated pulmonary embolism 
may originate from right atrial thrombi due to atrial fibrillation.  




Pulmonary embolism is generally thought to occur from silent or overt peripheral deep vein 
thrombosis (DVT), and the two conditions are commonly viewed as clinical manifestations of 
the same disease, i.e. venous thromboembolism (VTE). However, DVT is not found by 
ultrasonography or contrast venography in about half of patients with pulmonary embolism 
[1-3].  Recently, peripheral DVT was found in only 44% of patients with a first pulmonary 
embolism by advanced magnetic resonance imaging [4], further supporting the concept that 
pulmonary emboli additionally may arise from sites other than the deep veins, e.g. thrombi of 
cardiac origin, or by de novo formation of thrombi in the lung arteries. 
Atrial fibrillation is associated with thrombus formation in the left atrium with 
subsequent increased risk of systemic embolism, particularly ischemic stroke [5]. To what 
extent a similar phenomenon occurs in the right side of the heart (i.e. right-side intracardiac 
thrombosis) has not been extensively studied. However, spontaneous echocontrast has been 
noted in the right atrium of patients with right heart abnormalities such as atrial fibrillation 
[6,7], and autopsy studies have displayed clots in the right atrium of patients with atrial 
fibrillation during their last illness [8], supporting the concept that isolated pulmonary 
embolism may arise from intracardiac thrombi.  
The prevalence of atrial fibrillation in the general population is reported to be 2-3% 
[9], whereas the reported prevalence of atrial fibrillation ranges from 15 to 21% in patients 
with acute pulmonary embolism [10-12]. Despite this relatively frequent co-existence of 
pulmonary embolism and atrial fibrillation, the relationship between the two conditions has 
not been extensively investigated in prospective observational studies. In a large registry-
based nested case-control study, however, the prevalence of atrial fibrillation during 0-3 
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months prior to the index date was substantially higher in subjects with VTE than in controls 
[13].  
Abnormal haemostasis, including increased fibrin turnover and platelet activation, is 
well described in patients with atrial fibrillation [14], and the existence of this procoagulant 
state may promote development of thrombi in the deep veins. Moreover, right-side 
intracardiac thrombosis due to intra-atrial stasis can potentially lead to isolated pulmonary 
embolism. We therefore aimed to investigate whether atrial fibrillation was associated with 
future risk of VTE in a prospective cohort study with subjects recruited from a general 




Study participants were recruited from the fourth (1994-95), fifth (2001-02) and sixth survey 
(2007-08) of the Tromsø Study. To these surveys, the entire population (Tromsø 4) or parts 
(Tromsø 5 and 6) of the population aged ≥25 years living in the municipality of Tromsø, 
Norway, were invited to participate. A detailed description of study participation has been 
published elsewhere [15]. The overall attendance rate was high, ranging from 77% in Tromsø 
4 to 66% in Tromsø 6. A total of 30 586 subjects aged 25-97 years participated in at least one 
of the surveys. The regional committee of medical and health research ethics approved the 
study, and all subjects gave their written consent to participate. Subjects who did not give 
their written consent to medical research (n=225), those not officially registered as inhabitants 
of the municipality of Tromsø at date of study enrolment (n=47), and subjects with VTE 
(n=76) or atrial fibrillation (n=263) before baseline were excluded. Accordingly, a total of 
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29 975 subjects were included in the study, and were followed from the date of study 
inclusion until the end of follow-up, December 31, 2010 (figure 1). 
 
BASELINE MEASUREMENTS 
Baseline information about study participants was collected by self-administered 
questionnaires, blood samples and a physical examination. Questionnaires were used to obtain 
information on smoking (current smoker yes/no), history of arterial cardiovascular disease 
(CVD) (angina pectoris, myocardial infarction or stroke) and diabetes. Non-fasting blood 
samples were collected and serum total cholesterol, triglycerides and high density lipoprotein 
(HDL) measured as previously described. Systolic and diastolic blood pressure were 
measured three times with 1 minutes intervals with an automatic device (Dinamap Vital Signs 
Monitor, 1846, Critikon Inc., Tampa, FL, USA) in a sitting position after 2 minutes of rest, 
and defined here as the mean of the last two readings. Height and weight were measured with 
subjects wearing light clothes and no shoes. Body mass index (BMI) was calculated as weight 
in kilograms divided by the square of height in meters (kg/m2). 
 
ATRIAL FIBRILLATION: IDENTIFICATION AND VALIDATION 
Incident events of atrial fibrillation occurring during follow-up were identified by the hospital 
discharge diagnosis registry at the University Hospital of North Norway (included diagnoses 
from hospitalizations and outpatient clinic) and by the National Causes of Death registry, 
using the International Classification of Disease version 9 (ICD-9) codes 427.0-427.99 and 
ICD-10 codes I47-I48. In addition, a search through medical records of patients with 
cardiovascular disease and cerebrovascular events was performed [16]. The diagnosis of atrial 
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fibrillation had to be documented by an electrocardiogram, and adjudication of the events was 
performed by an independent endpoint committee. Classification of atrial fibrillation into 
paroxysmal and persistent versus permanent forms was performed when possible. Subjects 
having a paroxysmal course of atrial fibrillation initially, but who later developed a permanent 
form, were classified as having permanent atrial fibrillation. Subjects who could neither be 
classified as paroxysmal or persistent, and subjects with transient atrial fibrillation occurring 
only during an acute myocardial infarction or in connection with cardiac surgery, and subjects 
with atrial fibrillation documented only in the terminal phase (the last week) of life were 
defined as “other atrial fibrillation”. 
 
VENOUS THROMBOEMBOLISM: IDENTIFICATION AND VALIDATION 
All incident VTE events during follow-up were identified by searching the hospital 
discharge diagnosis registry, the autopsy registry and the radiology procedure registry at the 
University Hospital of North Norway as previously described [17]. The University Hospital of 
North Norway is the only hospital in the region, and all diagnostic radiology and hospital care 
is provided exclusively by this hospital. The medical record for each potential case of VTE 
was reviewed by trained personnel, and a VTE event was considered verified and recorded 
when presence of clinical signs and symptoms of DVT or pulmonary embolism were 
combined with objective confirmation tests (by compression ultrasonography, venography, 
spiral computed tomography, perfusion-ventilation scan, pulmonary angiography, autopsy), 
and resulted in a VTE diagnosis that required treatment, as previously described in detail [17]. 
VTE cases from the autopsy registry were recorded when the death certificate indicated VTE 
as cause of death or a significant condition associated with death. The VTE events were 
classified as provoked and unprovoked depending on the presence of provoking factors at the 
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time of diagnosis. Provoking factors were recent surgery or trauma within the previous 8 
weeks, acute medical conditions (acute myocardial infarction, ischemic stroke or major 
infectious disease), active cancer, immobilization (bed rest >3 days, wheelchair use or long-
distance travel exceeding 4 hours within the last 14 days prior to the event) or any other 
factors described by a physician in the medical record (e.g. intravascular catheter).  
 
STATISTICAL ANALYSES 
Subjects who developed atrial fibrillation during the study period contributed with non-
exposed person time from the baseline inclusion date to the date of a diagnosis of atrial 
fibrillation, and then with exposed person time from the date of atrial fibrillation and onwards. 
Subjects who had incident atrial fibrillation and VTE on the same day (n=7) were excluded 
from the analyses since the temporal sequence of events could not be determined in these 
subjects. For each participant, non-exposed and exposed person-years were counted from the 
date of enrolment (1994-95, 2001-02 or 2007-08) to the date of an incident VTE event, the 
date the participant died or moved from the municipality of Tromsø, or until the end of the 
study period, December 31, 2010, whichever came first. Subjects who died (n= 3546) or 
moved from Tromsø (n=4297) during follow-up were censored at the date of migration or 
death.  
Statistical analyses were performed with STATA version 12.0 (Stata corporation, 
College Station, TX, USA). Crude incidence rates (IR) of VTE were calculated and expressed 
as number of events per 1000 person-years at risk. Incidence rate differences were calculated 
by subtracting the incidence rate among non-exposed from the exposed (Iexposed-Inon-exposed). 
Cox proportional hazard regression models were used to obtain crude and multivariable 
adjusted hazard ratios (HR) for VTE with 95% confidence intervals (CI). Age was used as 
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time-scale and the subjects’ age at study enrolment was defined as entry-time, and exit-time 
was defined as age at date of VTE diagnosis, date of death, date of migration or date of study 
end. The exposure variable atrial fibrillation (yes/no) was included as a time-dependent 
variable, i.e. all subjects were initially classified with no atrial fibrillation at study entry, and 
the variable was updated in subjects who experienced an atrial fibrillation during follow-up. 
Hazard ratios of VTE according to time since diagnosis of atrial fibrillation (<6months and 
≥6months) were calculated. The HRs were adjusted for potential confounders including sex, 
BMI, smoking status, diastolic blood pressure, cholesterol levels, self-reported CVD and 
diabetes. In addition, IRs and HRs for pulmonary embolism and DVT were calculated 
separately. The number of subjects included in the adjustment models varied slightly due to missing 
data for co-variates (<2% missing). The proportional hazard assumption was tested using 
Schoenfeld residuals. Statistical interactions between atrial fibrillation and sex were tested by 
including cross-product terms in the proportional hazards model. No statistical interactions 
between atrial fibrillation and sex were found.  
Correct assessment of the temporal sequence of events was especially important in this 
study since atrial fibrillation potentially can be both the cause and the consequence of 
pulmonary embolism, and patients can present with the two conditions concomitantly. In the 
main analysis all incident VTEs that occurred ≥1 day after the diagnosis of atrial fibrillation 
were considered as potentially caused by the atrial fibrillation. In order to investigate whether 
the association was still present when the temporal sequence was unambiguous, we conducted 
additional sensitivity analysis where only VTE events that occurred more than 7 days after 





Overall, we identified 1604 (5.4%) subjects with validated diagnosis of incident atrial 
fibrillation. A total of 614 subjects (2.0%) had an incident VTE event during a median of 15.6 
years (range: 1 day to 16.3 years) of follow-up. Among those with atrial fibrillation, 65 
subjects (4.0%) experienced a subsequent VTE. Characteristics of the study participants at 
baseline are shown in table 1. Subjects who were diagnosed with atrial fibrillation during 
follow-up were on average almost 20 years older than those with neither atrial fibrillation nor 
VTE, and 6 years older than those with a VTE only (Table 1).  
Characteristics of the VTE events are shown in table 2. Among patients with atrial 
fibrillation, 55% were pulmonary embolisms and 45% were deep vein thrombosis. In contrast, 
the corresponding proportions in those without atrial fibrillation were 37% and 67%, 
respectively (Table 2). The proportion of unprovoked VTE events was higher in those without 
atrial fibrillation (45%) than in those with atrial fibrillation (31%). Active cancer and 
immobilization were the most frequent provoking factors among subjects without atrial 
fibrillation (22.6% and 20.0%, respectively), while acute medical conditions and 
immobilization were most frequent among those with atrial fibrillation (32.3% and 30.8%, 
respectively). 
Incidence rates and hazard ratios for VTE among subjects with and without atrial 
fibrillation during follow-up are displayed in Table 3 and Figure 2. Among the subjects with 
atrial fibrillation, 65 suffered a subsequent VTE.  The incidence rate of VTE was highest 
during the first 6 months after the atrial fibrillation diagnosis (35 per 1000 person-years) 
(Figure 2), the risk was 8-fold higher in those with atrial fibrillation compared to those 
without atrial fibrillation (HR: 8.44, 95% CI: 5.61-12.69). Furthermore, the incidence rate of 
VTE in the period ≥6 months up to 15 years after atrial fibrillation was 6.3 per 1000 person-
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years, and the risk of VTE was 43% increased (HR 1.43, 95% CI: 1.03-1.99). Adjustments for 
BMI, smoking, total cholesterol, diastolic blood pressure, self-reported CVD and diabetes 
slightly attenuated the risk estimates. Separate analysis of pulmonary embolism and DVT 
showed that the risk of both outcomes was remarkably high during the first 6 months after the 
atrial fibrillation diagnosis (Table 3). The multivariable HR was 11.17 (95% CI: 6.41-19.49) 
for pulmonary embolism and 6.01 (95% CI: 3.27-11.06) for DVT. The risk of pulmonary 
embolism remained 1.8-fold higher in those with atrial fibrillation in the period from 6 
months throughout follow-up (HR 1.83, 95% CI 1.16-2.90), whereas there was apparently no 
association between atrial fibrillation and risk of DVT more than 6 months after the atrial 
fibrillation diagnosis (HR 1.04, 95% CI: 0.64-1.68).  
In the sensitivity analyses, 9 VTE events that occurred less than one week after onset 
of atrial fibrillation were excluded. Using this approach, the risk estimate for the first 6 
months was somewhat attenuated, but still, atrial fibrillation was associated with a more than 
5-fold higher risk of VTE (HR: 5.19, 95% CI: 3.14-8.60) and of pulmonary embolism (HR: 
5.59, 95% CI: 2.60-12.1) after multivariable adjustments.  
Incidence rates and hazard ratios of VTE according to different types of atrial 
fibrillation are shown in Table 4. All types of atrial fibrillation were associated with increased 
risk of VTE and followed essentially the same risk pattern as overall atrial fibrillation. 
Persistent atrial fibrillation exhibited the highest incidence rates and relative risk estimates, 






We found that patients with atrial fibrillation had increased risk of subsequent venous 
thromboembolism. The incidence rate and relative risk was especially high during the first 6 
months after atrial fibrillation was diagnosed. Atrial fibrillation was associated with increased 
risk of both deep vein thrombosis and pulmonary embolism, during the first 6 months. In the 
period after 6 months there was no longer an association with DVT, whereas the risk of 
pulmonary embolism remained 80% higher in those with atrial fibrillation compared to those 
without atrial fibrillation. All sub-types of atrial fibrillation were associated with VTE, and 
displayed an essentially similar risk pattern. 
Except for our population-based cohort study, only one previous register study has 
investigated the sequential relationship between atrial fibrillation and VTE. In coherence with 
our findings, Sørensen et al.[13] showed that the prevalence of atrial fibrillation/flutter was 
substantially higher in patients with VTE, and especially isolated pulmonary embolism, 
compared with population controls in a large registry-based case-control study. The 
association was particularly strong when a discharge diagnosis of atrial fibrillation was 
observed less than 3 months before the index date (OR 23.5 for isolated pulmonary embolism 
and 15.2 for isolated DVT) [13]. Several other observational studies support these findings. A 
history of atrial fibrillation was found in 20% of cases with pulmonary embolism, although 
the temporal sequence of the events had not been determined in these studies [10-12]. An 
Italian cross-sectional study of 11 236 patients with pulmonary embolism reported higher 
prevalence of heart diseases, including atrial fibrillation, among elderly (>60 years) patients 
with a diagnosis of isolated pulmonary embolism compared to those with pulmonary 
embolism and concurrent DVT [18]. Later case-control analysis of patients with unprovoked 
pulmonary embolism revealed that atrial fibrillation or flutter was 1.5-fold more prevalent in 
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patients with isolated pulmonary embolism compared to patients with pulmonary embolism 
and concurrent DVT [19].    
 In our study, atrial fibrillation exhibited higher risk estimates for pulmonary 
embolism than of DVT, particularly in the period more than 6 months after atrial fibrillation 
diagnosis. This finding supports the theory that isolated pulmonary embolism in atrial 
fibrillation patients may originate from right side intracardiac thrombi. Spontaneous 
echocontrast has been noted in the right atrium of patients with atrial fibrillation [6,7], and has 
been positively associated with perfusion defects assessed by pulmonary scintigraphy [20].  In 
a large Swedish autopsy study, an intracardiac thrombus was found in 12% of the subjects 
with pulmonary embolism compared with 6% in the matched controls [21]. Right side 
intracardiac thrombosis was identified as the only source of emboli in 4% of all patients with 
pulmonary embolism [21].  Later, right heart thrombi were confirmed by echocardiography in 
4% of patients with acute pulmonary embolism [22].  In addition to intra-atrial stasis and 
thrombus formation, haemostatic changes promoting both platelet and coagulation activity are 
well-described in patients with atrial fibrillation [14,23,24]. 
The risk of both DVT and pulmonary embolism was particularly high during the first 
6 months after diagnosis of atrial fibrillation. Several factors may explain this phenomenon. A 
delay in the initiation of rhythm and rate control along with hesitance to immediately 
introduce anticoagulant treatment may subject individuals to a higher risk in the early phase 
after diagnosis of atrial fibrillation. Moreover, circumstantial conditions such as concomitant 
hospitalization and other co-morbidities may contribute to excessive VTE risk in the initial 
phase.  
Major strengths of this study include the large number of participants recruited from a 
general population, the well validated information on exposure and outcome, and 
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measurements of potential confounders. Putatively, atrial fibrillation can be both the cause 
and the consequence of pulmonary embolism, as a pulmonary embolism may trigger atrial 
fibrillation through right atrial distension, stress or hypoxia. The temporal sequence of 
diagnoses was well-assessed in our study, and in sensitivity analyses we found that atrial 
fibrillation was still associated with increased risk of VTE when the minimum time between 
the atrial fibrillation diagnosis and onset of VTE was more than one week. The study has 
some limitations that merit attention. Paroxysmal atrial fibrillation has been reported to be 
asymptomatic in a substantial amount of patients [25]. Thus, undetected paroxysmal episodes 
may still have preceded VTE, and thereby resulted in an underestimation of the risk estimates 
in our study. Potential confounders such as BMI and co-morbidities were assessed at baseline 
only, and these factors may have changed over time. Moreover, the observed association 
could potentially be confounded or mediated by concurrent development of other diseases 
such as congestive heart failure, infections, chronic obstructive pulmonary disease or chronic 
kidney disease. Unfortunately, we did not have information on use of oral anticoagulant 
therapy in patients with atrial fibrillation. However, a previous study from our hospital 
conducted in the period 1995-1998 reported that 70% of those discharged with a diagnosis of 
chronic atrial fibrillation were treated with oral anticoagulants and 20% with platelet 
inhibitors [26]. Oral anticoagulant treatment efficiently reduces the risk of VTE [27,28]. 
Therefore, it is likely that the true risk of VTE after atrial fibrillation is underestimated in our 
study, i.e. that the association between atrial fibrillation and VTE was even stronger in 
untreated patients. 
In conclusion, patients with atrial fibrillation had higher risk of venous 
thromboembolism compared to subjects without atrial fibrillation, and the risk was 
particularly high for both deep vein thrombosis and pulmonary embolism during the first six 
months following a diagnosis of atrial fibrillation. After 6 months, atrial fibrillation was still 
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associated with increased risk of pulmonary embolism, but not with deep vein thrombosis. 
Our findings support the hypothesis that isolated pulmonary embolism may arise from 
intracardiac thrombi formed in patients with atrial fibrillation.    
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Figure 1. Inclusion of study participants from the fourth (1994/95), fifth (2001/02) and sixth (2007/08) survey of the Tromsø study. 
 
Figure 2: Hazard ratios (HR) with 95% confidence interval (CI) of venous thromboembolism (VTE) according to time periods after a diagnosis 
of atrial fibrillation. The Tromsø Study. 
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Table 1. Baseline characteristics of subjects without and with atrial fibrillation and/or venous thromboembolism (VTE) during follow-up. Values 
are given as absolute numbers with percentages in brackets or as means with standard deviation in brackets. The Tromsø Study. 
 
No atrial 







Atrial fibrillation and 
subsequent VTE  
during follow-up 
Subjects (n) 27815 1539 549 65 
Sex (male) (%) 13066 (47.0) 863 (56.1) 252 (45.9) 31 (47.7) 
Age (years) 45.2±14.0 63.8±11.7 57.8±14.2 66.0±9.5 
BMI (kg/m2) 25.2±3.9 26.9±4.3 26.9±4.4 27.6±3.9 
Total cholesterol (mmol/l) 5.92±1.29 6.67±1.24 6.61±1.35 6.77±.1.11 
Triglycerides (mmol/l) 1.53±1.04 1.76±.08 1.70±0.92 1.88±1.19 
HDL (mmol/l) 1.49±0.41 1.51±0.44 1.51±0.42 1.55±0.37 
Systolic blood pressure (mmHg) 132±20 152±24 143±23 151±25 
Diastolic blood pressure (mmHg) 77±12 86±14 82±13 86±14 
Smoking (%) 10122 (36.4) 413 (26.9) 174 (31.8) 22 (33.8) 
Physical activity (%) 9236 (33.7)   297 (19.5) 119 (21.8)  8 (12.5) 
Self-reported CVD (%) 1364 (4.9) 360 (23.5) 66 (12.0)  13 (20.0) 




Table 2. Characteristics of the incident VTE events (n=614) during follow-up. The Tromsø 
Study. 
 No atrial fibrillation Atrial fibrillation 
 % (n) % (n) 
Venous thromboembolism 549 65 
Age at VTE diagnosis (years, mean (SD)) 67 (14) 77 (10) 
Sex (% men) 252 (45.9) 31 (47.7) 
Deep vein thrombosis 345 (62.8) 29 (44.6) 
Pulmonary embolism 204 (37.2) 36 (55.4) 
Unprovoked  246 (44.8) 20 (30.8) 
Clinical risk factors   
Estrogena 37 (6.7)  1 (1.5) 
Pregnancy/puerperiuma 6 (1.1) - 
Heredityb 20 (3.6) - 
Other medical conditionsc 11 (20.0) 24 (36.9) 
Provoking factors   
Surgery  86 (15.7) 12 (18.5) 
Trauma 39 (7.1) 5 (7.7) 
Acute medical conditionsd 63 (11.5) 21 (32.3) 
Cancer 124 (22.6) 12 (18.5) 
Immobilitye 110 (20.0) 20 (30.8) 
Otherf 23 (4.2) 4 (6.2) 
a Only women included in analysis  
b VTE in first degree relative before aged 60 years. 
c Includes other diseases within the previous year (myocardial infarction, ischemic stroke, 
heart failure, inflammatory bowel disease, chronic infections, chronic obstructive pulmonary 
disease, or myeloproliferative disorders). 
d Includes myocardial infarction, ischemic stroke or major infectious disease. 
e Immobility includes bed rest>3days, longtime travels with car, boat, train or by air >4 hours 
within last 14 days, or other type of immobilization. 




Table 3. Incidence rates and hazard ratios for total VTE, pulmonary embolism and DVT in subjects developing atrial fibrillation 
during follow-up compared to subject without atrial fibrillation. The Tromsø Study. 
 Person- Years Events 
Crude 
IR (95% CI) 
Model 1a  
HR (95% CI) 
Model 2b  
HR (95%CI) 
Total VTE      
No atrial fibrillation 358845 549 1.5 (1.4-1.7) Ref Ref 
<6 months after atrial fibrillation 712 25 35.1 (23.7-51.9) 8.44 (5.61-12.69) 8.09 (5.37-12.18)  
≥6 months after atrial fibrillation 6369 40 6.3 (4.6-8.6) 1.43 (1.03-1.99) 1.35 (0.98-1.89) 
Pulmonary embolism     
No atrial fibrillation 358845 204 0.6 (0.5-0.7) Ref Ref 
<6 months after atrial fibrillation 712 14 19.6 (11.6-33.2) 11.84 (6.80-20.63) 11.17 (6.41-19.49) 
≥6 months after atrial fibrillation 6369 22 3.5 (2.3-5.3) 1.96 (1.24-3.10) 1.83 (1.16-2.90) 
DVT      
No atrial fibrillation 358845 345  1.0 (0.9-1.1) Ref Ref 
<6 months after atrial fibrillation 712 11 15.4 (8.6-2.8) 6.20 (3.37-11.39) 6.01 (3.27-11.06) 
≥6 months after atrial fibrillation 6369 18 2.8 (1.8-4.4) 1.08 (0.66-1.75) 1.04 (0.64-1.68) 
a using age as time-scale and adjusted for sex. 





Table 4. Incidence rates and hazard ratios for venous thromboembolism (VTE) according to type of atrial fibrillation. The Tromsø 
Study. 




IR (95% CI) 
Model 1a  
HR (95% CI) 
Model 2b  
HR (95%CI) 
Paroxysmal atrial fibrillation      
No atrial fibrillation 358845 549 1.5 (1.4-1.7) Ref Ref 
<6 months after atrial fibrillation 297 8 26.9 (13.4-53.7) 6.67 (3.30-13.47) 6.59 (3.26-13.32)  
≥6 months after atrial fibrillation 2666 17 6.4 (4.0-10.3) 1.43 (0.88-2.34) 1.41 (0.86-2.31) 
Persistent atrial fibrillation     
No atrial fibrillation 358845 549 1.5 (1.4-1.7) Ref Ref 
<6 months after atrial fibrillation 278 11 39.5 (21.8-71.4) 9.01 (4.93-16.49) 8.18 (4.47-14.98) 
≥6 months after atrial fibrillation 2686 19 7.0 (4.5-11.1) 1.56 (0.98-2.49) 1.41 (0.88-2.25) 
Other atrial fibrillation      
No atrial fibrillation 358845 549 1.5 (1.4-1.7) Ref Ref 
<6 months after atrial fibrillation 137 6 43.9 (19.7-97.7) 11.0 (4.87-24.64) 10.8 (4.82-24.40) 
≥6 months after atrial fibrillation 1016 4 3.9 (1.5-10.4) 0.96 (0.36-2.59) 0.96 (0.36-2.56) 
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